Descrizione del progetto
Nanoparticelle multifunzionali per il trattamento del morbo di Parkinson
Il morbo di Parkinson è un disturbo neurodegenerativo correlato alla perdita di neuroni dopaminergici e all’accumulo intra-neuronale di alfa-sinucleina (αS). L’apporto di determinati fattori neurotrofici al cervello blocca e inverte la neurodegenerazione nei modelli animali, ma questi fattori non attraversano la barriera emato-encefalica e devono essere somministrati mediante microchirurgia. La strategia di cura del morbo di Parkinson è basata sull’eliminazione della αS e sulla prevenzione della sua aggregazione patologica. I risultati preliminari hanno mostrato che le nanoparticelle d’oro rivestite con beta-caseina riducono l’aggregazione di αS possono essere utilizzate per somministrare i fattori neurotrofici nel cervello. Il progetto NEUROCURE, finanziato dall’UE, si propone di sviluppare un trattamento per il morbo di Parkinson a base di nanoparticelle d’oro multifunzionali che limiterà la progressione della malattia correlata ad αS e favorirà la sopravvivenza dei neuroni dopaminergici, somministrando fattori neurotrofici nel cervello.
Obiettivo
Parkinson’s disease (PD) is the second most common neurodegenerative disorder that is characterised by progressive loss of dopamine neurons and abnormal intra-neuronal accumulation of protein α-synuclein (αS). None of the available treatments have shown ability to slow down the progression of the neurodegeneration. One of the therapeutically potent approaches to combat PD is neurotrophic factor (NTF)-based therapies. Delivery of NTFs to the brain shows a notable therapeutic potential due to the ability to stop and reverse neurodegeneration in animal models. The most potent NTFs for PD therapy so far are CDNF and GDNF that have been recently studied in clinical trials on PD patients. Despite of the promising results, CDNF and GDNF does not pass through the blood brain barrier (BBB) and should be delivered to the brain through a risky microsurgery. Thus, there is a great need for an effective method that can deliver CDNF/GDNF through the BBB avoiding intracranial surgery. Another promising strategy for curing PD is based on αS clearance and control of its pathological aggregation and propagation. Our preliminary results showed that beta-casein coated AuNPs have great capacity to reduce αS aggregation and can be used to deliver NTFs to the brain. This proposal combines nanomedicine and molecular neurobiology to develop multi-functional AuNP-based medicine against PD that will positively impact the disease progression through mitigation of the parthenogenesis associated with αS and support the survival of dopamine neurons by CDNF/GDNF delivery to the brain. The applicant will get training needed for his future independent research career through hands-on training in the top scientific laboratories and by managing the highly innovative research at the interface of different disciplines connecting two excellent scientists: Prof. Saarma, a world leading molecular neurobiologist and Prof. Teesalu, an expert in homing peptides.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinatore
00014 Helsingin Yliopisto
Finlandia